Abstract
GCI Oncology Suite v2.3–v2.4 expands the v2.1 delivery platform with additional open‑hardware modules designed to increase therapeutic transport into solid tumors. Bench testing, phantom‑model evaluations, and literature‑derived comparisons indicate 3.4× to 12× delivery improvements relative to published benchmarks for chemotherapy, immunotherapy, ADCs, and solid‑tumor CAR‑T. New integrations include real‑time cavitation‑dose gating (#127 Guardian), Acoustic Cluster Therapy (ACT), lactate‑responsive nanoparticles, microbubble‑FUS plasma monitoring, and a FUS‑assisted Panobinostat transport module. Hardware additions total $7K and maintain a full system BOM of $52K. Modeled survival‑curve extensions across multiple tumor types are based on delivery‑scaling simulations rather than clinical outcomes. All hardware and documentation are released under CERN‑OHL‑P for humanitarian replication and global research use.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Caldwell, Michael Victor Mr., "GCI Oncology Suite v2.3–v2.4: Multi‑Modal Delivery Architecture and Open‑Hardware Performance Benchmarks (CERN‑OHL‑P)", Technical Disclosure Commons, (March 05, 2026)
https://www.tdcommons.org/dpubs_series/9462